Carbon Ion RT for Locally Advanced Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label randomized trial. Subjects will be randomized in a 2:1 ratio to receive
carbon ion radiotherapy versus standard care for locally advanced pancreatic cancer. Subjects
who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the
discretion of the treating physicians. Subjects on the control arm are also expected to
receive chemotherapy, using a regimen selected by the treating physicians. Subjects on the
control arm will not receive upfront radiotherapy but may receive radiotherapy (not carbon
ion radiotherapy) if disease progression occurs.